Sid Scudder (Roche Molecular CA) Liquid biopsy for EGFR, the cobas EGFR Mutation Test v2 the long and winding road #Tricon
2:05pm February 22nd 2017 via Hootsuite
Luthra: Concludes by introducing liquid biopsy as an atlernative: CTC, exosomes, ctDNA and ctRNA #Tricon
Luthra: 10% insufficient tissue; sampling error and bias '12 NEJM https://t.co/hcPJSmLBE2 63% missed due to sampling heterogeneity #Tricon
2:03pm February 22nd 2017 via Hootsuite
Raja Luthra (MD Anderson TX) Tumor genotyping is the current Gold Standards - TAT typically 4-5d, but add'l weeks to get tissues #Tricon
2:01pm February 22nd 2017 via Hootsuite
Bischoff: Growing evidence demonstrating surragacy to tumor tissue biopsy; repeatable throughout Rx #Tricon
12:23pm February 22nd 2017 via Hootsuite
Bischoff: Liquid biopsy is turned to when tissue is not available or insufficient. Early evidence of resistance, recurrance. #Tricon
12:22pm February 22nd 2017 via Hootsuite
Bischoff: FFPE 20-25% failure in NGS; FISH 10-15% biomarker inconclusive; TILs have complex infiltration #Tricon
12:21pm February 22nd 2017 via Hootsuite
Bischoff: Points out FFPE tissue has challenges in both pre-analytical and heterogeneity in analysis #Tricon
12:20pm February 22nd 2017 via Hootsuite
Farideh Bischoff (Chief Clin Dev Officer) Digital cell sorting and recovery - standardization of sample preparation #tricon
12:18pm February 22nd 2017 via Hootsuite
Ferree: Down to PD-1/PD_L1; Lag3, TIM3, IDO Blockade; MDSC targeting Carbo/Taxol; Treg; Wnt inh, PI3K inh; HDAC inh; CTLA-4 inh #Tricon
12:16pm February 22nd 2017 via Hootsuite
Ferree: Shows slide of their vision for a universal immune-oncology assay - T-cell inflamed ("hot") and "cold" branches #Tricon
12:15pm February 22nd 2017 via Hootsuite
Ferree: Pathway, Immune profiling, and Progression panels cover the Hanahan hallmarks of cancer #Tricon
12:13pm February 22nd 2017 via Hootsuite
Ferree: Current testing paradigm of one test, one drug, wasteful. Core research use panel: PanCancer, 770-plx covering all hallmarks #Tricon
12:12pm February 22nd 2017 via Hootsuite
Sean Ferree (VP Development NanoString) Discovering again and again, how complex cancer biology is. #Tricon
12:11pm February 22nd 2017 via Hootsuite
Garlick: Products for solid sumor @SeraCare with SNVs, Indels, RNA fusions, coming soon - CNVs. ctDNA w/NIST; inh disease #Tricon
12:09pm February 22nd 2017 via Hootsuite
Garlick: NGS Dx has many QC checkpoints, and require a 'truth set'. Fernandes pointed out pre-analytical and bioinf variables #Tricon
12:08pm February 22nd 2017 via Hootsuite
Garlick: NIPS error rate is 3.8% (!) for published data https://t.co/ACQnNUR2yW #Tricon
12:06pm February 22nd 2017 via Hootsuite
Garlick: Need proficiency testing, modernized CLIA. The broad idea, sharing of data. Rehm rev '16: https://t.co/3hpjEEHzvE #Tricon
12:05pm February 22nd 2017 via Hootsuite
Garlick: Points out that goals like the Cancer Moonshot need faster and more accurate disease genotyping. Reporting: need truth sets #Tricon
12:03pm February 22nd 2017 via Hootsuite
Russell Garlick (CSO SeraCare) Advancing Next Generation Sequencing Technology #Tricon
12:02pm February 22nd 2017 via Hootsuite
Vossenaar: One user in Milan: Went from 3-4 weeks TAT, to a single day. Many pts in Italy have to travel to see oncologists #Tricon
12:00pm February 22nd 2017 via Hootsuite
Vossenaar: Thus Idylla NB- I blogged about the system Nov '15 here: https://t.co/qoeumvxLmh #Tricon
11:59am February 22nd 2017 via Hootsuite
Vossenaar: AstraZeneca compared 12 methods for KRAS - from RT-qPCR, MALDI-TOF, NGS< ddPCR, and Sanger #Tricon
11:58am February 22nd 2017 via Hootsuite
Vossenaar: 1/4 pts start of 1st line Rx are before test results, including insufficient tissue. Shows chart comparing methods #Tricon
Erik Vossenaar (VP BioCartis): Molecular medicine for every patient #Tricon
11:55am February 22nd 2017 via Hootsuite
Ferrara: Will oncology informatics drive providers to accept more risk for oncology care? #Tricon
11:53am February 22nd 2017 via Hootsuite
Ferrara: Will payers value an informatics solution, or just view it as the cost of business? #Tricon
11:52am February 22nd 2017 via Hootsuite
Ferrara: Can the clin and econ evidence the value of informatics in oncology care? Value of ID new care options? Outcomes? #Tricon
Ferrara: Clin NGS may be losing money at the lab level, but at the system level adds a lot of value. #Tricon
11:51am February 22nd 2017 via Hootsuite
Ferrara: Emphasis on broader evidence-based economic impact, practice level impace, clinical outcomes. #Tricon
Ferrara: And financial risk has shifted to providers as well. Pay for perf, quality, pt demographics. Shared savings, paid bundles #Tricon
11:50am February 22nd 2017 via Hootsuite
Ferrara: Integrated delivery networks (IDNs); 70% of oncologists are in IDNs in '10. Vast amt of spending at IDN #Tricon
11:49am February 22nd 2017 via Hootsuite
Ferrara: Pace of innovation in Dx and Rx; molecular testing, targeted Rx = info overload for physicians #Tricon
11:48am February 22nd 2017 via Hootsuite
Ferrara: Information intensive part supports Rx selection, outcomes. Technology / service providers, and detailed activities #Tricon
Ferrara: Key driver is targeted Rx for cancer care; more tests. Targeted in '13 is now 46% of cancer care. 5y OS for CML now 89% #Tricon
11:46am February 22nd 2017 via Hootsuite
Ferrara: Oncology is a top cost concern for payers. '10 cancer was $125B in direct medical costs; $173B by '20 #Tricon
11:45am February 22nd 2017 via Hootsuite
Joe Ferrara (Pres, Boston Healthcare) Value capture in Oncology Informatics #Tricon
11:44am February 22nd 2017 via Hootsuite
Rubin: Additional dimensions are cost, CLIA waivers, compatibility of materials, enabling technology vs productivity increase #Tricon
11:43am February 22nd 2017 via Hootsuite
Rubin: Shows three dimensions - technology challenges, device complexity, and regulatory as three to optimize time-to-market #Tricon
11:42am February 22nd 2017 via Hootsuite
Rubin: Add to list: Multi-color fluorescence and alignment of optics; single-cell technology; POC and UIX; connectivity, portability #Tricon
11:39am February 22nd 2017 via Hootsuite
Rubin: Laundry list of dev challenges - sample prep, disposables, miniturization, detection of MEMS, optics; imaging, throughput #Tricon
11:38am February 22nd 2017 via Hootsuite
Rubin: Customers may have a biomarker and need an instrument; or sample prep for NGS; or dPCR, CTCs. Antibiotic suscept #Tricon
11:34am February 22nd 2017 via Hootsuite
Dick Rubin (VP Accel Biotech) is a contract mfr of analytical tools for life sciences; from dPCR to CTCs to CE to chromatography #Tricon
11:33am February 22nd 2017 via Hootsuite
Ianelli: Points to Kayak (flight search) as an example of how platform works - based upon tissue, type of specimen, sliders etc #Tricon
11:31am February 22nd 2017 via Hootsuite
Mueller: But to derive value, they need to be accessed. Since '12: EMR, cloud compute, and marketplaces (AMZN, eBay) #Tricon
11:29am February 22nd 2017 via Hootsuite
Ianelli: In '09, Biobanking had a lot of hype, 'Number 8 on a list of 10 ideas changing the world' #Tricon
11:28am February 22nd 2017 via Hootsuite
Ianelli: Pulls info from Path and Clin labs, repositories and clin research; and interfaces with industry and academia #Tricon
11:26am February 22nd 2017 via Hootsuite
Christopher Ianelli (CEO iSpecimen MA) a biospecimen marketplace paltform for boht healthcare providers and lifescience researchers #Tricon
11:25am February 22nd 2017 via Hootsuite
Mueller: https://t.co/1fR2wslDqA is their website for more info #Tricon
11:24am February 22nd 2017 via Hootsuite
Mueller: Gives a use case of @iontorrent workflow, integrating Torrent APIs and BioBuilds w/open source tools for mapping, calling #Tricon
